NCT06845540

Oral Metformin for Treating Melasma in Latin American Women

Oral Metformin in the Treatment of Melasma: a Prospective Trial in Latin American Women

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of Puerto Rico · Academic / Other
• Sex: Female
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if metformin can treat melasma in Latin American women. The main question it aims to answer is: \- Can metformin help reduce the dark patches of melasma? Researchers will test two different doses of metformin (500 mg and 1000 mg) to see if either one helps improve melasma. Participants will: * Take a metformin pill every day for three months. * Go to the clinic twice: once at the beginning and once at the end of the study. * Get a phone call from the researchers to check how they're doing and ask about any changes or side effects.

Conditions

• Melasma

Interventions

Type	Name	Description
DRUG	Metformin	Participants received oral metformin tablets for the treatment of melasma. The initial dose was 500 mg once daily for four weeks. At week 4, participants who tolerated the medication well increased their dose to 500 mg twice daily for the remaining eight weeks of the study. Participants were instructed to avoid other melasma treatments during the trial and to use sunscreen (SPF 30 or higher) daily.

Timeline

• Start date: 2025-02-20
• Primary completion: 2025-05-22
• Completion: 2025-05-30
• First posted: 2025-02-25
• Last updated: 2025-02-25

Locations

1 site across 1 country: Puerto Rico

Regulatory

• FDA-regulated drug study